Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP231312.RA37PT6mp32qrBkEyzT6SzH7Znvz2f4PE3raphi2ZYs0g130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP231312.RA37PT6mp32qrBkEyzT6SzH7Znvz2f4PE3raphi2ZYs0g130_assertion type Assertion NP231312.RA37PT6mp32qrBkEyzT6SzH7Znvz2f4PE3raphi2ZYs0g130_head.
- NP231312.RA37PT6mp32qrBkEyzT6SzH7Znvz2f4PE3raphi2ZYs0g130_assertion description "[Several reports have demonstrated the persistent detection of AML1-MTG8 fusion products, representing minimal residual disease (MRD), in patients with t(8;21) acute myelogenous leukaemia (AML) who are in long-term remission.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP231312.RA37PT6mp32qrBkEyzT6SzH7Znvz2f4PE3raphi2ZYs0g130_provenance.
- NP231312.RA37PT6mp32qrBkEyzT6SzH7Znvz2f4PE3raphi2ZYs0g130_assertion evidence source_evidence_literature NP231312.RA37PT6mp32qrBkEyzT6SzH7Znvz2f4PE3raphi2ZYs0g130_provenance.
- NP231312.RA37PT6mp32qrBkEyzT6SzH7Znvz2f4PE3raphi2ZYs0g130_assertion SIO_000772 11122105 NP231312.RA37PT6mp32qrBkEyzT6SzH7Znvz2f4PE3raphi2ZYs0g130_provenance.
- NP231312.RA37PT6mp32qrBkEyzT6SzH7Znvz2f4PE3raphi2ZYs0g130_assertion wasDerivedFrom befree-20140225 NP231312.RA37PT6mp32qrBkEyzT6SzH7Znvz2f4PE3raphi2ZYs0g130_provenance.
- NP231312.RA37PT6mp32qrBkEyzT6SzH7Znvz2f4PE3raphi2ZYs0g130_assertion wasGeneratedBy ECO_0000203 NP231312.RA37PT6mp32qrBkEyzT6SzH7Znvz2f4PE3raphi2ZYs0g130_provenance.